| Wissenschaftl. Titel | A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer |
| Erkrankung |
Gyn:
Mamma-Ca:
Erstlinie
|
| Molekularer Marker |
PD-L1 |
| Kurzprotokoll | Kurzprotokoll |
erstellt 25.04.2024 Data entry III CCP
geändert 25.04.2024 Data entry III CCP